Rallybio Corporaton (RLYB) Stock Price, Quote & News

Company Profile

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-tar...

Industry: Biotechnology

Sector: Healthcare

Phone: 203 859 3820

Website: www.rallybio.com

Address:

234 Church Street, Suite 1020, New Haven, United States

FreeBeerTomorrow Feb. 6 at 5:41 AM

$RLYB * Rallybio Corporation (RLYB) is undergoing a 1-for-8 reverse stock split today, February 6, 2026. Ratio: 1-for-8 . Estimated Post-Split Float: ~4.68 million shares.

0 · Reply

PSM_EmpowerTrading Feb. 6 at 4:53 AM

🌅 Watchlist part 2 ✅ $ASST 1:20 reverse split, new price ≈ $9.40 ✅ $RLYB 1:8 reverse split, new price ≈ $4.64 ✅ $PRFX 1:5 reverse split, new price ≈ $3.20 🚨 Notes 🚨 The above tickers are not ideal for swing accumulation at current price ✅ Ideal long entry near low current support 🎯 Ideal stop loss if below current support 🚨 Avoid chasing into strength near resistance ⏳⏳ $NNOX $NRSN still in swing accumulation phase 🎯🎯 Goal: GR🤑🤑N, not GR🥵🥵D

0 · Reply

TwongStocks Feb. 5 at 9:13 PM

I am aware of four NASDAQ reverse split scheduled on Friday. Expect trading to halt at 7:50pm ET tonight and resume at 9:00am ET Friday morning. $ADIL 1 for 25. Will reduce outstanding shares from approx 27.8m to approx 1.1m $ASST 1 for 20. Will reduce outstanding Class A shares from approx 1.05B to approx 52.48m and outstanding Class B shares from approx 197.91m to approx 9.9m $PRFX 1 for 5. Will reduce outstanding shares from approx 3.92m to approx 783k $RLYB 1 or 8. Will reduce outstanding shares from approx 42.24m to approx 5.28m

2 · Reply

skyrockets_Inc Feb. 5 at 9:11 PM

$RLYB Currently $1.35/share in stockholder equity, no debt. Equates to approx. $10.80/share tomorrow after split. Always remember :)

0 · Reply

skyrockets_Inc Feb. 5 at 7:40 PM

$RLYB I think the only risk with the Cohort 2 would be safety since it's 300mg versus 150mg in Cohort 1. Obviously efficacy will be better at the higher dose. They did test a single ascending dose of 300mg back in 2023 and it had no major safety issues, but that was a single dose, not weekly. More importantly, the company would have seen the 4 week data of Cohort 2 at the end of Dec (when they originally guided to release the data)....if there were major safety concerns I FEEL like they would have seen them after 4 weeks and would have had to release the 'bad' news in December...it's an assumption but seems likely the hold up is either A). working out a deal or B). saw some minimal signs of antibodie creation and want to check at the 14 week mark to make sure no major issues that far out. As far as when to buy, I loaded up pre-RS just because afterwards 1:8 split the OS will be 5.25m and 81% is locked by tutes and insiders ..so free float will be less than 1M.

1 · Reply

isu2b3vrysus Feb. 5 at 5:22 PM

$RLYB I know that the first part of the 116 trial was positive - however, what are the actual odds of the second one being positive? I feel like there is a lot of positive sentiment on this board without much data. All that being said, I do like RLYB quite a bit, and I will probably take a position. Do yall think it would be better to buy before or after the split tomorrow?

1 · Reply

TwongStocks Feb. 4 at 9:10 PM

$RLYB Equity Corporate Actions Alert #2026 - 71 Information Regarding the Reverse Stock Split and CUSIP Number Change for Rallybio Corporation (RLYB) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-71 Rallybio Corporation (RLYB) will effect a one-for-eight (1-8) reverse split of its Common Stock. The reverse stock split will become effective on Friday, February 6, 2026. In conjunction with the reverse split, the CUSIP number will change to 75120L209.

0 · Reply

skyrockets_Inc Feb. 4 at 9:02 PM

$RLYB Data was due in Q3 and Q4 and has yet to be released (see red box below). Plans to start TWO Phase 2 trials in mid-2026 (see yellow box below). We have approx. 60M in cash right now, but completing two phase 2 trials will take a lot more $$. Completing 1:8 R/S this Friday to drop share count down to 5.25M. Theory: Data was withheld in order to do R/S first, drop share count down. Then release data, stock explodes, and they do a concurrent financing PIPE of 100M+ to push forward w/ the Phase 2 trials. It's just a waiting game at this point....

1 · Reply

skyrockets_Inc Feb. 3 at 9:42 PM

$RLYB Get ready for the nano-float on Friday :) "The reverse stock split is intended to give Rallybio greater flexibility in considering and PLANNING FOR FUTURE POTENTIAL BUSINESS NEEDS and to increase the per share trading price of the Rallybio common stock to enable Rallybio to satisfy the minimum price requirement for continued listing on the Nasdaq Capital Market" PIPE funding w/ nano-float sends this to Jupiter

1 · Reply

skyrockets_Inc Feb. 3 at 7:58 PM

$RLYB R/S this Friday. Then hopefully news within the following two weeks afterwards. Absolute last patient should be done w/ 10 week follow up by Feb 24 week. Analysis out possible outcomes below still stands and stock has been holding price. I've added more.

0 · Reply

Rallybio Announces Reverse Stock Split of Common Stock

Nov 6, 2025, 8:00 AM EST - 3 months ago

Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Sep 25, 2025, 8:00 AM EDT - 4 months ago

Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

Sep 3, 2025, 8:00 AM EDT - 5 months ago

Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program

Aug 7, 2025, 8:00 AM EDT - 6 months ago

Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jul 8, 2025, 9:44 AM EDT - 7 months ago

Why Is Microcap Rallybio Stock Trading Higher On Tuesday?

Jul 8, 2025, 8:00 AM EDT - 7 months ago

Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals

Jun 12, 2025, 8:00 AM EDT - 8 months ago

Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

May 8, 2025, 8:00 AM EDT - 9 months ago

Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates

Apr 29, 2025, 8:00 AM EDT - 10 months ago

Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference

Apr 8, 2025, 1:01 PM EDT - 10 months ago

Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints

Apr 8, 2025, 8:00 AM EDT - 10 months ago

Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT

Mar 13, 2025, 8:00 AM EDT - 11 months ago

Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Feb 25, 2025, 8:00 AM EST - 1 year ago

Rallybio to Present at the TD Cowen 45th Annual Health Care Conference

Feb 11, 2025, 8:00 AM EST - 1 year ago

Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial

Jan 10, 2025, 8:00 AM EST - 1 year ago

Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025

Dec 10, 2024, 8:00 AM EST - 1 year ago

Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting

Dec 2, 2024, 8:00 AM EST - 1 year ago

Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025

Nov 27, 2024, 8:00 AM EST - 1 year ago

Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women

Nov 26, 2024, 8:00 AM EST - 1 year ago

Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference

Nov 25, 2024, 8:00 AM EST - 1 year ago

Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor

Nov 21, 2024, 8:00 AM EST - 1 year ago

Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212

Nov 7, 2024, 8:00 AM EST - 1 year ago

Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT

Sep 30, 2024, 8:00 AM EDT - 1 year ago

Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting

Sep 23, 2024, 8:00 AM EDT - 1 year ago

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting

Sep 10, 2024, 8:00 AM EDT - 1 year ago

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit

Sep 9, 2024, 5:15 PM EDT - 1 year ago

Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree

Aug 29, 2024, 8:00 AM EDT - 1 year ago

Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis

Aug 27, 2024, 8:00 AM EDT - 1 year ago

National Vision Releases 2023 Sustainability Report

ACNT

Aug 27, 2024, 8:00 AM EDT - 1 year ago

Rallybio to Present at Upcoming Investor Conferences

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates

Jul 9, 2024, 8:00 AM EDT - 1 year ago

Rallybio to Present at the 2024 Jones Healthcare Seaside Summit

Jun 17, 2024, 8:00 AM EDT - 1 year ago

Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations

May 9, 2024, 8:00 AM EDT - 1 year ago

Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates

May 7, 2024, 8:00 AM EDT - 1 year ago

Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference

Apr 17, 2024, 4:01 PM EDT - 1 year ago

FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting

Apr 10, 2024, 4:01 PM EDT - 1 year ago

Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Apr 1, 2024, 10:05 AM EDT - 2 years ago

Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 26, 2024, 8:00 AM EST - 2 years ago

Rallybio to Present at the TD Cowen 44th Annual Health Care Conference

Feb 6, 2024, 8:00 AM EST - 2 years ago

Rallybio Announces Portfolio Prioritization and Provides Corporate Update

Jan 4, 2024, 8:00 AM EST - 2 years ago

Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024

Dec 20, 2023, 8:00 AM EST - 2 years ago

Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

Dec 9, 2023, 12:00 PM EST - 2 years ago

Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting

Nov 28, 2023, 7:00 AM EST - 2 years ago

Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia

Nov 9, 2023, 8:00 AM EST - 2 years ago

Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates

Nov 8, 2023, 8:00 AM EST - 2 years ago

Rallybio to Present at Upcoming Investor Conferences in November

Nov 2, 2023, 9:15 AM EDT - 2 years ago

Rallybio Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting

Oct 3, 2023, 8:00 AM EDT - 2 years ago

Rallybio to Present at the JonesTrading 2023 Healthcare Summit

FreeBeerTomorrow Feb. 6 at 5:41 AM

$RLYB * Rallybio Corporation (RLYB) is undergoing a 1-for-8 reverse stock split today, February 6, 2026. Ratio: 1-for-8 . Estimated Post-Split Float: ~4.68 million shares.

0 · Reply

PSM_EmpowerTrading Feb. 6 at 4:53 AM

0 · Reply

TwongStocks Feb. 5 at 9:13 PM

2 · Reply

skyrockets_Inc Feb. 5 at 9:11 PM

$RLYB Currently $1.35/share in stockholder equity, no debt. Equates to approx. $10.80/share tomorrow after split. Always remember :)

0 · Reply

skyrockets_Inc Feb. 5 at 7:40 PM

1 · Reply

isu2b3vrysus Feb. 5 at 5:22 PM

1 · Reply

TwongStocks Feb. 4 at 9:10 PM

0 · Reply

skyrockets_Inc Feb. 4 at 9:02 PM

1 · Reply

skyrockets_Inc Feb. 3 at 9:42 PM

1 · Reply

skyrockets_Inc Feb. 3 at 7:58 PM

0 · Reply

joe77w Feb. 1 at 2:00 PM

$RLYB https://clinicaltrials.gov/study/NCT06797375

0 · Reply

joe77w Jan. 31 at 1:35 AM

$RLYB any deal happening would be minimal for 10 USD consideration Just my opinion, investors Will Chase stock when and if news out, lets Hope well! Since dec19 within 60 trading days shares (options) become exercisable. Its a matter of patience and we should receive the hoped news about deal and trial data!🤞

0 · Reply

joe77w Jan. 31 at 1:29 AM

$RLYB 7 USD in cash After reverse split occurred on fully diluted basis

0 · Reply

estatebuyersmia Jan. 30 at 10:41 PM

$RLYB NO DEAL... HOPIUM.... I WAS RIGHT

1 · Reply

estatebuyersmia Jan. 30 at 10:40 PM

$RLYB MY TAKE, THE STOCK DRIFTS UNTIL DATA RELEASE

0 · Reply

skyrockets_Inc Jan. 30 at 7:22 PM

$RLYB Enter now while you can, next Friday after 1:8 R/S OS will be 5.25m and free float less than 1M (81% locked up w/ tutes and insiders), will be very difficult to build your position after R/S.

0 · Reply

skyrockets_Inc Jan. 30 at 12:37 AM

$RLYB R/S is happening Feb 6 (latest possible date) and for only 1:8 split, reducing our OS from 42m to 5.25m shares. Data is more than a month behind schedule so the likely outcomes are now as follows (from most likely to least IMO): 1). Good data drop w/ concurrent PIPE financing announcement --> company continues stand alone --> stock explodes 2). Good data drop, stock trades much higher and they announce offering AH to raise money --> company continues stand alone --> stock trades higher 3). Buyout / asset sale. Still on the table even with upcoming split if terms of deal couldn't be finalized before Feb 6. Split would then have to happen just to keep us listed on NASDAQ until terms finalized --> stock EXPLODES 4). Reverse merger --> depending on terms of deal could trade sideways or x2+ based on previous similar RM's I've been involved in lately (BRNS, VYNE, etc). 5). Bad data, announce strategic alternatives --> stock maintains based on cash position and strat alt annoucement.

1 · Reply

skyrockets_Inc Jan. 29 at 10:33 PM

$RLYB Deal thesis off the table? LOL. Not even. R/S had to happen in 2 out of the 3 scenarios. If they are RM'ing or releasing data and PIPEing then both would need R/S. They HAVE to do R/S by Feb 9, so any deal taking place after that will require the R/S. This has been known and repeated many times. If you truly believe this means 'deal off table' I'm expecting you will be selling your shares tomorrow. I will gladly buy them off of you :)

1 · Reply

BiotechValues Jan. 29 at 10:23 PM

$RLYB knew it. 1:8 RS effective next Friday. Deal thesis off table, but hopefully they pump data later in Feb or March with 5M shares tiny float..

0 · Reply

skyrockets_Inc Jan. 29 at 9:38 PM

$RLYB Don't forget.... Company is only burning 3M per quarter since the workforce reduction in May. End of Sept, co. had 63M in stockholder equity so it's safe to assume now at the end of Jan probably have 59M. With 42m shares outstanding this equates to a liquidation book value of 1.40/share giving ZERO value to assets RLYB116 or Preclinical assets RLYB332 and RLYB114. Don't forget still are owed 5M more payment from Recursion for REV102. And we are currently trading at 0.65/share! Such a ridiculous value I had to add more shares today. News on the horizon and most likely is either buyout/asset sale, RM, or data readout w/ PIPE funding. Any resolution is a good one at these prices IMO!

0 · Reply

skyrockets_Inc Jan. 29 at 6:39 PM

$RLYB Possible R/S on the table and yet this is up 7% on a day where every other biotech is red. Yeah, like I said before R/S is a non-issue and smart investors know this. Hopefully news Monday :)

0 · Reply

skyrockets_Inc Jan. 29 at 6:02 PM

$RLYB This is the only thing green on my watchlist today. Blood red market day.

0 · Reply

Market Cap	24.30M
Revenue (ttm)	640,000.00
Net Income (ttm)	-57.78M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-9,028.13%
Debt to Equity Ratio	0.00

Volume	128,100
Avg Vol	173,910
Day's Range	N/A - N/A
Shares Out	42.24M
Stochastic %K	15%
Beta	-1.05
Analysts	Sell
Price Target	$1.00